海特生物
(300683)
| 流通市值：29.07亿 | | | 总市值：31.22亿 |
| 流通股本：1.22亿 | | | 总股本：1.31亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 131,887,548.36 | 602,284,306.91 | 438,429,234.33 | 286,449,829.65 |
| 营业收入 | 131,887,548.36 | 602,284,306.91 | 438,429,234.33 | 286,449,829.65 |
| 二、营业总成本 | 185,592,842.22 | 714,276,365.88 | 506,037,628.53 | 329,717,737.62 |
| 营业成本 | 79,251,260.71 | 345,055,053.02 | 244,729,599.06 | 164,681,566.06 |
| 税金及附加 | 1,419,717.48 | 5,469,446.57 | 3,910,419.48 | 2,729,895.95 |
| 销售费用 | 27,790,413.62 | 128,664,537.98 | 99,323,724.23 | 67,526,165.36 |
| 管理费用 | 49,435,452.57 | 113,325,557.66 | 73,081,178.99 | 48,416,899.27 |
| 研发费用 | 27,937,527.55 | 128,902,853.46 | 90,738,631.99 | 51,132,800.47 |
| 财务费用 | -241,529.71 | -7,141,082.81 | -5,745,925.22 | -4,769,589.49 |
| 其中:利息费用 | 1,188,866.78 | 2,394,817.77 | 1,716,648.02 | 1,088,856.22 |
| 其中:利息收入 | 1,616,714 | 9,991,678.67 | 7,788,983.64 | 6,107,337.43 |
| 加:公允价值变动收益 | 5,807,661.68 | 1,898,170.08 | 11,651,982.37 | 6,814,345.8 |
| 加:投资收益 | 239,113.29 | 15,685,876.32 | 2,986,990.7 | 2,147,846.27 |
| 资产处置收益 | -43,503.53 | -358,669.66 | -2,179,599.91 | 39,211.31 |
| 资产减值损失(新) | 17,702,519.53 | -60,124,394.46 | 1,685,549.35 | 3,112,195.94 |
| 信用减值损失(新) | 564,598.58 | -974,969.76 | 2,161,118.71 | 2,092,858.66 |
| 其他收益 | 1,544,394.17 | 12,793,021.16 | 8,228,476.2 | 6,276,583.36 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -27,890,510.14 | -143,073,025.29 | -43,073,876.78 | -22,784,866.63 |
| 加:营业外收入 | 3,745.91 | 172,058.02 | 121,845.45 | 112,148.84 |
| 减:营业外支出 | 559,249.92 | 9,085,109.69 | 6,220,852.65 | 2,045,491.47 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -28,446,014.15 | -151,986,076.96 | -49,172,883.98 | -24,718,209.26 |
| 减:所得税费用 | -10,954,342.19 | -23,742,672.79 | -19,556,716.17 | -11,901,090.58 |
| 六、净利润 | -17,491,671.96 | -128,243,404.17 | -29,616,167.81 | -12,817,118.68 |
| 持续经营净利润 | -17,491,671.96 | -128,243,404.17 | -29,616,167.81 | -12,817,118.68 |
| 归属于母公司股东的净利润 | -16,545,525.38 | -120,822,819.73 | -26,439,471.42 | -11,127,732.26 |
| 少数股东损益 | -946,146.58 | -7,420,584.44 | -3,176,696.39 | -1,689,386.42 |
| (一)基本每股收益 | -0.13 | -0.93 | -0.21 | -0.09 |
| (二)稀释每股收益 | -0.13 | -0.93 | -0.21 | -0.09 |
| 九、综合收益总额 | -17,491,671.96 | -128,243,404.17 | -29,616,167.81 | -12,817,118.68 |
| 归属于母公司股东的综合收益总额 | -16,545,525.38 | -120,822,819.73 | -26,439,471.42 | -11,127,732.26 |
| 归属于少数股东的综合收益总额 | -946,146.58 | -7,420,584.44 | -3,176,696.39 | -1,689,386.42 |
| 公告日期 | 2024-04-22 | 2024-04-22 | 2023-10-25 | 2023-08-31 |
| 审计意见(境内) | | 标准无保留意见 | | |